G-pen may aid hypoglycemia with type 1 diabetes

February 22, 2016

(HealthDay)—Mini-dose glucagon administered using a stable, ready-to-use G-Pen Mini glucagon may be an effective option for mild to moderate hypoglycemia in adults with type 1 diabetes, according to a study published online Feb. 9 in Diabetes Care.

Morey W. Haymond, M.D., from the Baylor College of Medicine in Houston, and colleagues evaluated mini-dose glucagon in 12 adults with type 1 using a stable, liquid, ready-to-use preparation. Subcutaneous doses of 75, 150, and 300 µg of nonaqueous glucagon were administered and, at 180 minutes, subjects received insulin, followed in 60 minutes by a second identical dose of glucagon.

The researchers found that for the 75-, 150-, and 300-µg doses, mean (fasting glucose concentrations [mg/dL] were 110, 110, and 109, respectively, increasing maximally at 60 minutes by 33, 64, and 95 mg/dL [all P < 0.001]). The administered post-insulin were 70, 74, and 70 mg/dL, respectively, with maximal increases of 19, 24, and 43 mg/dL post-glucagon administration (P < 0.02) at 45 to 60 minutes.

"Subcutaneous, nonaqueous, ready-to-use G-Pen Mini glucagon may provide an alternative to oral carbohydrates for the management of anticipated, impending, or mild hypoglycemia in adults with type 1 diabetes," the authors write.

Several authors disclosed financial ties to Xeris Pharmaceuticals, the maker of the G-Pen.

Explore further: Protein preload boosts vildagliptin's effects in diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Protein preload boosts vildagliptin's effects in diabetes

February 3, 2016
(HealthDay)—A protein preload enhances the glucose-lowering efficacy of vildagliptin in type 2 diabetes, according to a study published online Jan. 19 in Diabetes Care.

Artificial sweeteners produce no glucagon response

January 14, 2014
(HealthDay)—Artificial sweeteners do not produce any changes in glucose metabolism compared to a glass of water, according to a letter published in the December issue of Diabetes Care.

Early loss of glucagon response to hypoglycemia found in teens

June 22, 2012
(HealthDay) -- In adolescents with type 1 diabetes the glucagon response to hypoglycemia is lost as early as one month and at a median of eight months after diabetes diagnosis, according to a study published online June 14 ...

Glucagon, GLP-1 co-infusion can reduce appetite

June 25, 2014
(HealthDay)—Co-infusion of glucagon and glucagon-like peptide 1 (GLP-1) correlates with a reduction in appetite, and GLP-1 protects against glucagon-induced hyperglycemia in healthy volunteers, according to a study published ...

Glucose levels linked to cardiac surgery outcomes

January 23, 2016
(HealthDay)—For patients undergoing cardiac surgery, hyperglycemia is associated with worse outcomes for patients without diabetes, but with better outcomes for patients with insulin-treated diabetes, according to a study ...

Dextromethorphan plus sitagliptin promising in type 2 diabetes

September 21, 2015
(HealthDay)—Dextromethorphan combined with sitagliptin shows potential for treatment of type 2 diabetes mellitus, according to a study published online Sept. 12 in Diabetes, Obesity and Metabolism.

Recommended for you

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

New measure of insulin-making cells could gauge diabetes progression, treatment

August 10, 2017
Researchers at the University of Wisconsin-Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.

Pioneering immunotherapy shows promise in type 1 diabetes

August 9, 2017
It may be possible to 'retrain' the immune system to slow the progression of type 1 diabetes, according to results of a clinical trial published today in the journal Science Translational Medicine.

Online team-based game helps patients with diabetes lower blood glucose

August 8, 2017
Researchers from Brigham and Women's Hospital and the Veterans Affairs Boston Healthcare System have found that an online, team-based game designed to teach patients about diabetes self-management had a sustained and meaningful ...

Oxidative stress biomarkers don't always signal diabetes risk

August 7, 2017
High levels of compounds found in the body that are commonly associated with oxidative damage may actually be a good sign for some people, according to a recent review of multiple human studies led by an epidemiologist at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.